首页> 外文期刊>Allergy, Asthma & Immunology Research >Long-term Effects of Specific Allergen Immunotherapy Against House Dust Mites in Polysensitized Patients With Allergic Rhinitis
【24h】

Long-term Effects of Specific Allergen Immunotherapy Against House Dust Mites in Polysensitized Patients With Allergic Rhinitis

机译:特异性变应原免疫疗法对多敏感变应性鼻炎患者房尘螨的长期疗效

获取原文
       

摘要

Purpose Allergen-specific immunotherapy is the only currently available treatment to modify the natural history of allergic rhinitis (AR). If patients are polysensitized, it is difficult to identify the allergen causing the allergic symptoms. We evaluated the effectiveness of immunotherapy against house dust mites (HDMs) in AR patients polysensitized to both HDMs and seasonal allergens. Methods Thirty AR patients polysensitized to both HDMs and seasonal allergens (group A) and 30 patients sensitized to HDMs only (group B) were enrolled in this study. All subjects who received immunotherapy against HDMs for more than 2 years were evaluated by the multiple allergen simultaneous test (MAST) to determine the specific IgE level in luminescence units, total eosinophil counts in peripheral blood, serum total IgE, total nasal symptom scores, and the rhinoconjunctivitis quality of life questionnaire (RQLQ) before and after immunotherapy. Results There were no statistical differences in levels of total and specific IgE, or total eosinophil count between the two groups. The total nasal symptom scores, RQLQ and medication scores significantly decreased after immunotherapy in both groups, however no significant differences were noted between the two groups. Conclusions We determined that the primary causative allergen of AR in Seoul, Korea is perennial allergens, such as HDMs, rather than seasonal allergens. This study provides a reference for the selection of allergens to use in immunotherapy for polysensitized AR patients living in an urban environment.
机译:目的过敏原特异性免疫疗法是目前唯一可用于改变过敏性鼻炎(AR)自然病史的疗法。如果患者是多敏的,则很难确定引起过敏症状的过敏原。我们评估了对HDM和季节性变应原多敏感的AR患者的房尘螨(HDM)免疫疗法的有效性。方法本研究招募了30名对HDM和季节性变应原多敏感的AR患者(A组)和30名仅对HDMs致敏的患者(B组)。通过多重变应原同时测试(MAST)对所有接受了针对HDM的免疫疗法超过2年的受试者进行评估,以确定发光单位的特定IgE水平,外周血总嗜酸性粒细胞计数,血清总IgE,总鼻症状评分和免疫治疗前后的鼻结膜炎生活质量问卷(RQLQ)。结果两组之间的总IgE和特异性IgE或总嗜酸性粒细胞计数无统计学差异。两组在接受免疫治疗后,总的鼻部症状评分,RQLQ和药物评分均显着降低,但是两组之间没有显着差异。结论我们确定,韩国首尔市AR的主要致病原是多年生过敏原,例如HDM,而不是季节性过敏原。这项研究为选择过敏原用于居住在城市环境中的多敏AR患者的免疫疗法提供了参考。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号